Skip to main content

SRI, CCD Receive Phase I STTR to Develop Software for Tuberculosis Drug Discovery

Premium

SRI International and Collaborative Drug Discovery have received a Phase I Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases to develop computational tools for tuberculosis drug discovery research.

The one-year, $149,000 award will support the development of tools for a tuberculosis information repository.

When it is complete, the repository will contain inference and analysis tools that can facilitate tuberculosis drug development efforts through a combination of multiple databases, cheminformatics, and pathway-based analysis, SRI and CDD said.

Specifically, biological data derived from the repository will be combined with logic-based modeling and inference techniques developed by scientists at SRI and cheminformatics-based computational prediction techniques developed by CDD.

Barry Bunin, president and CEO of CDD, said in a statement that the project will make it possible for investigators to "mine the deposited data, search for new potential targets and lead molecules" from a "single centralized location."

Sean Ekins, collaborations director at CDD, added that the partnership with SRI will result in "a synergistic computational tool" that will be used for "hypotheses testing, knowledge sharing, data archiving, data mining, and drug discovery."

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.